Stocks to Watch. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the ...
PGIM Jennison Health Sciences Fund released its second quarter 2024 investor letter. A copy of the letter can be downloaded ...
An investigation, published in the journal The BMJ, found that the newly U.S. Food & Drug Administration-approved donanemab is linked ...
An investigation has uncovered alarming issues including increased mortality rates, absent safety records, dubious efficacy, ...
A BMJ investigation found seven of the eight doctors appointed by the US Food & Drug Administration (FDA) to review donanemab ...
Donanemab, manufactured by Eli Lilly (LLY), is the latest in a new class of anti-amyloid drugs that deliver antibodies to target beta-amyloid, a protein linked to Alzheimer's disease. Initially ...
A report published Wednesday in The BMJ questioned the safety and effectiveness of the Alzheimer’s disease drug Kisunla ...
According to the latest Morning Thoughts post, Eli Lilly’s Alzheimer’s drug, donanemab (brand name Kisunla), was approved in Japan for treating early symptomatic Alzheimer’s disease ...
An array of pharmaceutical pills with the company's logo on the bottle. According to the latest Morning Thoughts post, Eli Lilly’s Alzheimer’s drug, donanemab (brand name Kisunla), was approved in ...